Treatment effects of stimulant medication in young boys with fragile X syndrome
Open Access
- 14 June 2011
- journal article
- research article
- Published by Springer Nature in Journal of Neurodevelopmental Disorders
- Vol. 3 (3) , 175-184
Abstract
Fragile X syndrome (FXS) is the most common inherited form of intellectual disability and is caused by a CGG repeat expansion at Xq27.3 on the FMR1 gene. The majority of young boys with FXS display poor attention and hyperactivity that is disproportionate to their cognitive disability, and approximately 70% meet diagnostic criteria for attention-deficit/hyperactivity disorder. Psychopharmacology is employed with 82% of young males 5–17 years of age, with stimulant medication as the most common medication prescribed. This study evaluated the effects of stimulant medication on the academic performance, attention, motor activity, and psychophysiological arousal of boys with FXS, as well as the concordance of effects within individuals. Participants in this study included 12 boys with FXS who were treated with stimulants. Participants completed videotaped academic testing on two consecutive days and were randomly assigned to be off stimulants for 1 day and on stimulants the other day. On each day, multiple measures including academic performance, behavior regulation, and psychophysiological arousal were collected. Approximately 75% of participants performed better on attention and academic measures, and 70% showed improved physiological regulation while on stimulant medication. A high degree of concordance among measures was found. Lower intelligence quotient (IQ), but not age, correlated with greater improvements in in-seat behavior. IQ and age did not relate to on-task behaviors. The frequency and magnitude of response to stimulant medication in boys with FXS is higher than those reported for most children with non-specific intellectual disabilities and autism spectrum disorder.Keywords
This publication has 55 references indexed in Scilit:
- Roles of Fragile X Mental Retardation Protein in Dopaminergic Stimulation-induced Synapse-associated Protein Synthesis and Subsequent α-Amino-3-hydroxyl-5-methyl-4-isoxazole-4-propionate (AMPA) Receptor InternalizationJournal of Biological Chemistry, 2010
- The Novel Calcineurin Inhibitor CN585 Has Potent Immunosuppressive Properties in Stimulated Human T CellsJournal of Biological Chemistry, 2010
- Concurrent Validity of the Child Behavior Checklist DSM-Oriented Scales: Correspondence with DSM Diagnoses and Comparison to Syndrome ScalesJournal of Psychopathology and Behavioral Assessment, 2009
- Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndromeGene Therapy, 2009
- A pilot open label, single dose trial of fenobam in adults with fragile X syndromeJournal of Medical Genetics, 2009
- Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in miceProceedings of the National Academy of Sciences, 2007
- Arousal Modulation in Females with Fragile X or Turner SyndromeJournal of Autism and Developmental Disorders, 2007
- Psychopharmacology in fragile X syndrome—Present and futureMental Retardation and Developmental Disabilities Research Reviews, 2004
- Influence of stimulants on electrodermal studies in Fragile X syndromeMicroscopy Research and Technique, 2002
- A controlled trial of stimulant medication in children with the fragile X syndromeAmerican Journal of Medical Genetics, 1988